Progress in Understanding the Pathogenesis of Systemic Sclerosis with Lung Involvement: The Contribution of Proteomic StudiesCinzia Scambi1*, Lucia De Franceschi2, Silvia Bosello3, Paola Caramaschi1, Gianfranco Ferraccioli3 and Domenico Biasi1
- *Corresponding Author:
- Cinzia Scambi, MD, Ph.D
Department of Medicine, Section of Rheumatology
University of Verona and AOUI, Policlinico GB Rossi
P.le L Scuro, 10, 37134 Verona, Italy
E-mail: [email protected]
Received Date: November 14, 2011; Accepted Date: January 28, 2012; Published Date: January 31, 2012
Citation: Scambi C, Franceschi LD, Bosello S, Caramaschi P, Ferraccioli G, et al. (2012) Progress in Understanding the Pathogenesis of Systemic Sclerosis with Lung Involvement: The Contribution of Proteomic Studies. Rheumatology S1:004. doi: 10.4172/2161-1149.S1-004
Copyright: © 2012 Scambi C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Systemic sclerosis (SSc) is a chronic inflammatory disease involving the skin and various internal organs. SSc is characterized by microvascular dysfunction, activation of the immune system and tissue fibrosis. Endothelial cell damage seems to be the initiating factor, but the precise triggering events that underlie the development of the disease remain unclear.
Lung involvement is a frequent complication, which causes increased morbidity and mortality in patients with SSc. In particular, pulmonary arterial hypertension and interstitial lung disease are the two major clinical diseases that affect SSc patients, but the current treatments appear to have no satisfying effects on these pulmonary complications, until yet.
Recently researches using innovative technologies have highlighted several peptides that might contribute to better understand the underlying pathogenic mechanisms of pulmonary injury and could promote more effective therapeutic strategies for SSc patients. Here, we focus on the major proteomic studies on biological fluid from patients with SSc.